Clinical and Molecular Hepatology: 2023, vol: , issue:
1)- Vy H Nguyen, Isaac Le, Audrey Ha, Richard Hieu Le, Nicholas Ajit Rouillard, Ashley Fong, Surya Gudapati, Jung Eun Park, Mayumi Maeda, Scott Barnett, Ramsey Cheung, Mindie H Nguyen. Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study.Clinical and molecular hepatology. 2023, 29 (4): 1002-1012
2)- Ha Il Kim, Jihyun An, Seungbong Han, Ju Hyun Shim. Loco-regional therapies competing with radiofrequency ablation in potential indications for hepatocellular carcinoma: a network meta-analysis.Clinical and molecular hepatology. 2023, 29 (4): 1013-1028
3)- Jeongin Yoo, Heejin Cho, Dong Ho Lee, Eun Ju Cho, Ijin Joo, Sun Kyung Jeon. Prognostic role of computed tomography analysis using deep learning algorithm in patients with chronic hepatitis B viral infection.Clinical and molecular hepatology. 2023, 29 (4): 1029-1042
4)- Daphne J Theodorou, Stavroula J Theodorou, Ioannis V Mitselos. Letter regarding "Evidence-based hyponatremia management in liver disease".Clinical and molecular hepatology. 2023, 29 (4): 1043-1045
6)- Ji Young Ryu, Seon Ha Baek, Sejoong Kim. Correspondence on Letter regarding "Evidence-based hyponatremia management in liver disease".Clinical and molecular hepatology. 2023, 29 (4): 1048-1049
7)- Eileen L Yoon, Dae Won Jun. Correspondence on Letter regarding "Risk factors in nonalcoholic fatty liver disease".Clinical and molecular hepatology. 2023, 29 (4): 1050-1051
8)- Qiankun Luo, Pan Liu, Yifei Dong, Tao Qin. The role of the hepatic autonomic nervous system.Clinical and molecular hepatology. 2023, 29 (4): 1052-1055
9)- Gi-Ae Kim, Joon Ho Moon, Won Kim. Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity.Clinical and molecular hepatology. 2023, 29 (4): 831-843
10)- Eileen L Yoon, Dae Won Jun. Waiting for the changes after the adoption of steatotic liver disease.Clinical and molecular hepatology. 2023, 29 (4): 844-850
11)- Landon L Chan, Stephen L Chan. The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment.Clinical and molecular hepatology. 2023, 29 (4): 909-923
12)- Ji Young Ryu, Seon Ha Baek, Sejoong Kim. Evidence-based hyponatremia management in liver disease.Clinical and molecular hepatology. 2023, 29 (4): 924-944
13)- Hwa Kyung Byun, Changhwan Kim, Jinsil Seong. Carbon Ion Radiotherapy in the Treatment of Hepatocellular Carcinoma.Clinical and molecular hepatology. 2023, 29 (4): 945-957
14)- Sung Uk Lee, Tae Hyun Kim. Current evidence and the potential role of proton beam therapy for hepatocellular carcinoma.Clinical and molecular hepatology. 2023, 29 (4): 958-968
17)- Sang Min Yoon. Novel paradigm in the treatment of hepatocellular carcinoma: Anticipating breakthroughs with particle therapy.Clinical and molecular hepatology. 2023, 29 (4): 977-979
19)- Hyo-Cheol Kim. Chemoembolization combined with radiofrequency ablation is the best option for the local treatment of early hepatocellular carcinoma?Clinical and molecular hepatology. 2023, 29 (4): 984-986
20)- Hong-Kyu Kim, Sung-Jin Bae, Min Jung Lee, Eun Hee Kim, Hana Park, Hwi Seung Kim, Yun Kyung Cho, Chang Hee Jung, Woo Je Lee, Jaewon Choe. Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity.Clinical and molecular hepatology. 2023, 29 (4): 987-1001
21)- Yuri Cho, Jin Woo Choi, Hoon Kwon, Kun Yung Kim, Byung Chan Lee, Hee Ho Chu, Dong Hyeon Lee, Han Ah Lee, Gyoung Min Kim, Jung Suk Oh, Dongho Hyun, In Joon Lee, Hyunchul Rhim, . Transarterial chemoembolization for hepatocellular carcinoma: 2023 Expert consensus-based practical recommendations of the Korean Liver Cancer Association.Clinical and molecular hepatology. 2023, 29 (3): 521-541
22)- Xianhua Mao, Lung Yi Mak, Wai-Kay Seto. The latest evidence on the impact of fatty liver on liver-related outcomes and mortality in chronic hepatitis B.Clinical and molecular hepatology. 2023, 29 (3): 690-692
23)- Moon Haeng Hur, Yuri Cho, Do Young Kim, Jae Seung Lee, Gyoung Min Kim, Hyo-Cheol Kim, Dong Hyun Sinn, Dongho Hyun, Han Ah Lee, Yeon Seok Seo, In Joon Lee, Joong-Won Park, Yoon Jun Kim. Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis.Clinical and molecular hepatology. 2023, 29 (3): 763-778
24)- Jeayeon Park, Sung Won Chung, Yun Bin Lee, Hyunjae Shin, Moon Haeng Hur, Heejin Cho, Min Kyung Park, Jeonghwan Youk, Ji Yun Lee, Jeong-Ok Lee, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Tae Min Kim, Jeong-Hoon Lee. Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma.Clinical and molecular hepatology. 2023, 29 (3): 794-809
25)- Hassam Ali. Letter 1 regarding "Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma".Clinical and molecular hepatology. 2023, 29 (3): 813-814
26)- Amnuay Kleebayoon, Viroj Wiwanitkit. Letter 2 regarding "Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma".Clinical and molecular hepatology. 2023, 29 (3): 815-816
27)- Seul Ki Han, Soon Koo Baik, Moon Young Kim. Correspondence on Letter regarding "Non-alcoholic fatty liver disease: Definition and subtypes".Clinical and molecular hepatology. 2023, 29 (3): 817-819
28)- Joo Hyun Oh, Dong Hyun Sinn. Correspondence on Letter regarding "Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?".Clinical and molecular hepatology. 2023, 29 (3): 820
29)- Yee Hui Yeo, Jamil S Samaan, Wee Han Ng. Correspondence on Letter 1 regarding "Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma".Clinical and molecular hepatology. 2023, 29 (3): 821-822
30)- Yee Hui Yeo, Jamil S Samaan, Wee Han Ng. Correspondence on Letter 2 regarding "Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma".Clinical and molecular hepatology. 2023, 29 (3): 823-824
33)- Kyung-Ah Kim, Sejoon Lee, Hye Jung Park, Eun Sun Jang, Youn Jae Lee, Sung Bum Cho, Young Seok Kim, In Hee Kim, Byung Seok Lee, Woo Jin Chung, Sang Hoon Ahn, Seungtaek Kim, Sook Hyang Jeong. Erratum to 'Next-generation sequencing analysis of hepatitis C virus resistance-associated substitutions in directacting antiviral failure in South Korea' [Clin Mol Hepatol 2023;29:496-509].Clinical and molecular hepatology. 2023, 29 (3): 830
34)- Yee Hui Yeo, Ju Dong Yang. Disseminating Steatotic Liver Disease Patient Education: The Emerging Role of Large Language Models.Clinical and molecular hepatology. 2023, :
35)- Miguel Sogbe, Idoia Bilbao, Francesco P Marchese, Jon Zazpe, Annarosaria De Vito, Marta Pozuelo, Delia D'Avola, Mercedes IƱarrairaegui, Carmen Berasain, Maria Arechederra, Josepmaria Argemi, Bruno Sangro. Prognostic Value of Ultra-Low-Pass Whole-Genome Sequencing of Circulating Tumor DNA in hepatocellular carcinoma under systemic treatment.Clinical and molecular hepatology. 2023, :
36)- Xinyi Lu, Rui Yang, Yu Chen, Daozhen Chen. Evaluating the Therapeutic Efficacy of NAD Supplementation in Management of MASLD: Key Considerations.Clinical and molecular hepatology. 2023, :
39)- Shuhei Fukunaga, Michita Mukasa, Dan Nakano, Tsubasa Tsutsumi, Takumi Kawaguchi. Changing from NAFLD to MASLD: Similar Cumulative Incidence of Reflux Esophagitis between NAFLD and MASLD.Clinical and molecular hepatology. 2023, :
40)- Eileen L Yoon, Dae Won Jun. Correspondence on a Letter regarding "Waiting for the changes after the adoption of steatotic liver disease (MASLD)".Clinical and molecular hepatology. 2023, :
41)- Hyeyeon Hong, Won-Mook Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Jonggi Choi. Cardiovascular Risk in Chronic Hepatitis B Patients Treated with Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide.Clinical and molecular hepatology. 2023, :
43)- Kuo Chao Yew, Sunny H Wong, Vincent Wai-Sun Wong, Hazel H Oon. It is time to consider a new paradigm shift in Steatotic Liver Disease in Asia.Clinical and molecular hepatology. 2023, :
44)- Soomin Ahn, Sook-Hyang Jeong, Eun Ju Cho, Kyoungbun Lee, Gilhyang Kim, Haeryoung Kim. Comparison of four histological scoring systems for autoimmune hepatitis to improve diagnostic sensitivity.Clinical and molecular hepatology. 2023, :
46)- Kamya Sankar, Jun Gong, Arsen Osipov, Steven A Miles, Kambiz Kosari, Nicholas N Nissen, Andrew E Hendifar, Ekaterina K Koltsova, Ju Dong Yang. Recent advances in the management of hepatocellular carcinoma.Clinical and molecular hepatology. 2023, :
47)- Seon Ha Baek, Ji Young Ryu, Sejoong Kim. Erratum to 'Correspondence on Letter regarding "Evidencebased hyponatremia management in liver disease"' [Clin Mol Hepatol 2023;29:1048-1049].Clinical and molecular hepatology. 2023, :
48)- Hinpetch Daungsupawong, Viroj Wiwanitkit. Comment on "ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma.".Clinical and molecular hepatology. 2023, :
49)- Young Chang, Soung Won Jeong, Jae Young Jang. Recent Updates on Pharmacologic Therapy in Nonalcoholic Fatty Liver Disease.Clinical and molecular hepatology. 2023, :
50)- Chi Hsiao, Yung-Po Liaw. Letter regarding "Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma".Clinical and molecular hepatology. 2023, :